晶泰控股-P午前涨逾4% 与优时比签署大分子药物发现AI平台授权协议

新浪港股
Jan 13, 2025
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  晶泰控股-P(02228)午前上涨3.94%,现报4.48港元,成交额1.82亿港元。

  1月9日,晶泰控股-P宣布,其下属部门Ailux Biologics与总部位于比利时的跨国生物制药公司优时比(UCB)签署大分子药物发现AI平台授权协议。根据协议,晶泰科技商业授权UCB使用Ailux Biologics自主开发的 XtalFold AI平台进行大分子药物的发现和工程化设计。XtalFold是一套基于AI的软件平台,能够为大分子药物研发提供快速且准确的结构信息,在多个研发阶段加速创新。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10